Huntingdon

Driving Precision Medicine: Rising Demand for Single Cell Analysis Propels Global Market Growth to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023
COVID-19, Research, Genetics, Diabetes, Cardiology, Stem Cells, Biotechnology, Health, Science, Oncology, Bio-Rad Laboratories, Prevalence, Investment, SARS-CoV-2, Genomics, Cancer, Single-cell analysis, Medicine, Cell, Danaher Corporation, Competition, Becton, Dickinson and Company headquarters, Huntingdon, Compound annual growth rate, Neuroscience, Promega, NHLBI, HIV disease progression rates, Thermo Fisher Scientific, Application, Chronic condition, Consumables, Flow cytometry, Conditional sentence, Growth, Merck, Mindful Scientific Inc., Safety, Disease, Government, Pharmaceutical industry, Vaccine, Medical imaging, Illumina

The Global Single Cell Analysis Market is expected to experience substantial growth with a steady Compound Annual Growth Rate (CAGR) during the period of 2024 to 2028.

Key Points: 
  • The Global Single Cell Analysis Market is expected to experience substantial growth with a steady Compound Annual Growth Rate (CAGR) during the period of 2024 to 2028.
  • The growth of genomic and proteomic technologies has significantly influenced the expansion of the global single cell analysis market.
  • Chronic diseases, including cancer, cardiovascular conditions, and diabetes, are significant drivers of the global single cell analysis market.
  • Government funding plays a pivotal role in the growth of the global single cell analysis market.

The Netherlands is Europe's Connected Life Sciences & Health Metropolis

Retrieved on: 
Monday, June 5, 2023
MSD, International, Biotechnology, European Medicines Agency, University, Health, Research, Multimedia, Netherlands Foreign Investment Agency, Science, EMA, Huntingdon, Patient, European, Alnylam Pharmaceuticals, Kite Pharma, NFIA, Pharmaceutical industry, Fine chemical

WASHINGTON, June 5, 2023 /PRNewswire/ -- The Netherlands is a prime location for biotech companies that bring forth an open-minded, innovative and inclusive approach to novel challenges in life sciences and health. Companies that invest in Holland are innovating for the benefit of patients and society at large. This dynamic Dutch life sciences and health ecosystem will be on full display during the BIO International Convention in Boston on June 5-8, 2023.

Key Points: 
  • This dynamic Dutch life sciences and health ecosystem will be on full display during the BIO International Convention in Boston on June 5-8, 2023.
  • "International companies that have operations in the Netherlands work alongside Dutch life sciences and health partners to build a healthier world together.
  • The Netherlands' central European location and vibrant life sciences & health ecosystem helps drive solutions for the future of biotech and healthcare."
  • Life Sciences & Health companies can connect with Europe and the world from the Netherlands.

DDN and Helmholtz Munich Host 2023 Life Sciences Field Day to Share Research Insights and Best Practices

Retrieved on: 
Thursday, April 13, 2023
Latest Trends, Data management, Gottfried Wilhelm Leibniz, Genetics, Ministry of Telecommunication, Digital Infrastructure and Foreign Employment, Challenge, Institute of technology, Biotechnology, Agriculture, Partner Institute for Computational Biology, Research, Organization, Science, DDN, Artificial intelligence, Leibniz Prize, AI, Huntingdon, Computational biology, Medical device

CHATSWORTH, Calif., April 13, 2023 /PRNewswire/ -- DDN®, the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced its 2023 Life Sciences Field Day, hosted by Helmholtz Munich on May 4, 2023 at the Helmholtz Munich campus.

Key Points: 
  • Join Leading Life Sciences Innovators at the Helmholtz Munich Campus to Discuss the Latest Trends, Challenges and Solutions in Data Management, Storage and Analysis
    CHATSWORTH, Calif., April 13, 2023 /PRNewswire/ -- DDN ® , the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced its 2023 Life Sciences Field Day , hosted by Helmholtz Munich on May 4, 2023 at the Helmholtz Munich campus.
  • The 2023 Life Sciences Field Day is a unique opportunity for innovators, researchers, and industry leaders.
  • "We are thrilled to bring together leading minds in life sciences research to gather and share knowledge, experiences, and best practices at the 2023 Life Sciences Field Day," said Tommaso Cecchi, senior director of Sales EMEA, DDN.
  • "We are honored to host the 2023 Life Sciences Field Day with the purpose of accelerating the transfer from ideas to applications with experts from across the life sciences community."

Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 5, 2022
Biotechnology, Pharmaceutical, Health, Medium (website), Research, Thermo Fisher Scientific, Gene, Genetics, Virology, Vaccine, Protein, Regenerative medicine, Comprehension, Virus, Huntingdon, Population density, Hormone, Genetic engineering, Cell, Region, Insulin, Immunotherapy, CAGR, A-DNA, B cell, Biochemistry, Growth, Drug development, Fine chemical

The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements.

Key Points: 
  • The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements.
  • The growing need for animal-free supplements in cell culture applications is aiding the growth of the recombinant cell culture supplements market.
  • Recombinant cell culture supplements play a crucial role in enhancing cell viability, maintaining a healthy culture, and customizing the cell culture in accordance with the needs of the individual.
  • Increasing demand for immunotherapy and stem cell and regenerative medicine research is one of the major opportunities in the recombinant cell culture supplements market.

Specialty Networks Partners with Datavant to Bring Real-world Specialty Data to Life Sciences Research through its SoNaR Registry

Retrieved on: 
Tuesday, April 12, 2022
Family, Inflammatory bowel disease, Friction, Psoriasis, Rheumatism, Sonar, Rheumatology, Research, Center, Organization, GLOBE, Osteoarthritis, Patient, Gastroenterology, SAN, Time-invariant system, Technology, Privacy, Center of excellence, Health, List of life sciences, Solution, Huntingdon, Neoplasm, Eurosport 1, Urology, Overactive bladder, Hope, James Whale Fund for Kidney Cancer, Physician, Population Health Management, Industry, Disease, Partnership, Prostate, Medicine, Medical imaging

Leveraging Datavants ecosystem of more than 500 real-world data partners, Specialty Networks will link other data sources like claims, labs, imaging, mortality events, and social determinants to create a complete longitudinal patient journey.

Key Points: 
  • Leveraging Datavants ecosystem of more than 500 real-world data partners, Specialty Networks will link other data sources like claims, labs, imaging, mortality events, and social determinants to create a complete longitudinal patient journey.
  • SoNaR Specialty Networks Registry represents the family of highly curated specialty registries in urology, gastroenterology, and rheumatology for various tumors and disease states.
  • Specialty Networks is establishing a gold standard in urology for real-world evidence research with its SoNaR registry and technology stack that integrates a large proportion of independent community physician practices across the country.
  • Specialty Networks (SN) is an integrated, multi-specialty organization with GPOs, Life Sciences, and Research solutions in urology, gastroenterology, and rheumatology.

WEKA Increases Funding to $140 Million to Accelerate AI Data Platform Adoption in the Enterprise

Retrieved on: 
Saturday, February 5, 2022
Networks, Data Management, Other Technology, Technology, Software, Cloud, Engineering, Ecosystem, AI, DEC Alpha, CPU, Enterprise, Growth, Research, Graphics processing unit, Hewlett Packard Enterprise, Organization, Hitachi, Digital, List, Artificial intelligence, Sustainability Accounting Standards Board, Cisco Systems, HPC, Magic Quadrant, Machine learning, Deep learning, CEO, Customer data platform, Pathfinder, Gartner, Health, Board, CIOS, Entrepreneurship, Technology, Acceleration, Capital, GPU, Data infrastructure, Huntingdon, Solution, Micrometre, Hewlett-Packard, Video game console, Financial services, Cryptocurrency, Asset management, NVIDIA, WEKA, Networks, Data Management, Other Technology, Technology, Software

WEKA, the data platform for AI, today announced that Hitachi Ventures led its recent round raising $73 million in funding, which brings the total amount raised to $140 million.

Key Points: 
  • WEKA, the data platform for AI, today announced that Hitachi Ventures led its recent round raising $73 million in funding, which brings the total amount raised to $140 million.
  • "GPUs and accelerated computing technologies are rapidly replacing traditional CPU compute at 100-1000 times performance, shifting the AI bottleneck from CPU access to data access, and creating a huge market opportunity for WEKAs modern Data Platform for AI.
  • With the explosion of unstructured data and the migration of AI workloads from on-prem to cloud, WEKA is delivering what its customers need better than anyone - a Data Platform for AI with unlimited scale and unrivaled performance.
  • WEKA helps the enterprise solve big IT infrastructure problems to accelerate business outcomes and speed productivity.

WEKA’s FY21 Wrap – Here We GROW Again!!!

Retrieved on: 
Thursday, December 16, 2021
Data Management, Technology, Software, Networks, Internet, Hardware, STAC, Magic, Organization, Solution, Hitachi, GTM, Interface, Intelligence, CSI, Exascale computing, Science, Weka, AI, Happiness, Byte, Customer data platform, CEO, APAC, WEKA, Research, Machine learning, API, THANK, Supermicro, HPE, Investment, EMEA, Huntingdon, Engineering, Remote backup service, REST, HPC, File system, Health, AWS, Management, Toy, Video game console, Video game, Kubernetes

As we look back at fiscal-year 2021, WEKA continued to grow at an unimaginable rate.

Key Points: 
  • As we look back at fiscal-year 2021, WEKA continued to grow at an unimaginable rate.
  • In Q4 of FY21 alone, WEKA had more deals than all of 2020 combined.
  • WEKA is on a mission to replace decades of compromises with a new Data Platform built for AI and Modern Workloads.
  • WEKAs Go-To-Market strategy is unique, we build solutions with the largest on-premises and public cloud vendors in the world.

Weka and Hewlett Packard Enterprise Provide Jointly Validated Solution for Containerized Workloads

Retrieved on: 
Tuesday, December 7, 2021
Data Management, Technology, Software, Networks, Internet, Hardware, DAS, NVM Express, Solution, Huntingdon, Architecture, HPC, Research, HPE, GPU, Economics, Blog, ISV, Hewlett Packard Enterprise, GTM, View, Organization, Partnership, Data management, ML, Flash, Disc, WIN, Adoption, NAS, Ecosystem, Enterprise, AI, Investment, Medical device, Video game console, Risk management

WekaIO (Weka), the data platform for AI, today announced that it has developed a high-performance solution with Hewlett Packard Enterprise (HPE) for the most demanding AI and ML workloads.

Key Points: 
  • WekaIO (Weka), the data platform for AI, today announced that it has developed a high-performance solution with Hewlett Packard Enterprise (HPE) for the most demanding AI and ML workloads.
  • This new Ezmeral validated Weka solution is in addition to the existing HPE ProLiant validated solutions currently available from HPE at HPE Solutions for Weka .
  • Weka is excited about partnering with HPE to enable solutions with Wekas scalable parallel file system on HPE Ezmeral Runtime Enterprise.
  • WekaIO, WekaFS, Weka AI, Weka Innovation Network, Weka Within, Weka AI logo, WIN logo, Weka Within logo, and the WekaIO logo are trademarks of WekaIO, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005125/en/

Latest Weka Features Extend Capabilities of Visionary Data Platform

Retrieved on: 
Thursday, December 2, 2021
Data Management, Technology, Other Technology, Software, Networks, Internet, DAS, HPC, VMware, CEO, AI, EC2, NAS, VM, CSI, Remote backup service, WIN, Software, View, Huntingdon, Research, Investment, NVM Express, Elasticity, Organization, Budget, AWS, Video game console, Computer data storage

One single data platform offers the simplicity of NAS, the performance of SAN or DAS and the scale of object storage along with accelerating every stage of the data pipeline from data ingestion to cleansing to modeled results.

Key Points: 
  • One single data platform offers the simplicity of NAS, the performance of SAN or DAS and the scale of object storage along with accelerating every stage of the data pipeline from data ingestion to cleansing to modeled results.
  • The Weka development model ensures that we continue to improve the product on a rapid basis and the latest features are an extension of our capabilities to better help users unlock the full capabilities of their data centers.
  • Those looking to learn more or leverage the latest features are encouraged to contact one of the companys Weka Innovation Network partners for additional information.
  • WekaIO, WekaFS, Weka AI, Weka Innovation Network, Weka Within, Weka AI logo, WIN logo, Weka Within logo, and the WekaIO logo are trademarks of WekaIO, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005264/en/

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Retrieved on: 
Thursday, December 2, 2021
Risk, Analysis, MYC, Biology, Diagnosis, Result, Financial condition report, IGHV, Physician, Bortezomib, Time, DNA, Chimeric antigen receptor T cell, B-cell maturation antigen, Bone marrow, Dexamethasone, Acute lymphoblastic leukemia, Follicular lymphoma, CAR, Completeness, Kinetics, BCL2, Cancer, Multiple myeloma, Blood, ALL, DNA sequencing, Treatment, Conversation, Research, Huntingdon, Chronic lymphocytic leukemia, Melphalan, Infection, CLIA, Subgroup, Fluctuating asymmetry, BCMA, MM, MRD, Progression-free survival, Safety, LDT, Terminology, FDA, Relapse, Recurrence, Drug discovery, Lymphatic system, De novo, Whole blood, Genetics, Disease, CLL, Medical imaging, Dietary supplement, Vaccine, Pharmaceutical industry

Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment.

Key Points: 
  • Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment.
  • In August 2020, clonoSEQ received additional clearance from the FDA to detect and monitor MRD in blood or bone marrow from patients with CLL.
  • The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies.
  • For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary .